Article
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.
Cancer research - 15 Sept 2023
Marín Arnaldo, Mamun Abdullah Al, Patel Hima, Akamatsu Hiroaki, Ye Dan, Sudhan Dhivya R, Eli Lisa, Marcelain Katherine, Brown Benjamin P, Meiler Jens, Arteaga Carlos L, Hanker Ariella B
Abstract excerpt
HER2 mutations drive the growth of a subset of breast cancers and are targeted with HER2 tyrosine kinase inhibitors (TKI) such as neratinib. However, acquired resistance is common and limits the durability of clinical responses. Most HER2-mutant breast cancers progressing on neratinib-based therapy acquire secondary mutations in HER2. It is unknown whether these secondary HER2 mutations, other than the HER2T798I...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.